Harman Patil (Editor)

Leo Pharma

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Area served
  
Worldwide

Revenue
  
7.973 billion DKK (2014)

CEO
  
Gitte Aabo (1 Jan 2008–)

Number of employees
  
4,712

Key people
  
Gitte Aabo (CEO)

Headquarters
  
Ballerup, Denmark

Founded
  
1908

Leo Pharma httpsuploadwikimediaorgwikipediaen33dLog

Type
  
Aktieselskab A/S Danish Public Limited stock based corporation

Industry
  
Pharmaceutical industry

Products
  
Prescription drugs for dermatology, bone remodeling thrombosis and coagulation

Total assets
  
31.627 billion DKK (2014)

Founders
  
August Kongsted, Anton Antons

Subsidiaries
  
LEO LABORATORIES LIMITED, LEO Pharma Inc.

Profiles

Leo pharma helping people in the real world


Leo Pharma A/S is a multinational Danish pharmaceutical company, founded in 1908, with a presence in about 100 countries. Its headquarters are in Ballerup, near Copenhagen The company is 100% integrated into a private foundation owned by the LEO Foundation. Leo Pharma develops and markets products for dermatology, bone remodeling thrombosis and coagulation. In 1945 it was the first producer of penicillin outside the USA and UK.

Contents

Formation & the 20th Century

In 1908, pharmacists August Kongsted and Anton Antons bought the LEO Pharmacy in Copenhagen, Denmark. With the purchase, they established 'Københavns Løveapoteks kemiske Fabrik', today known as LEO Pharma. LEO Pharma celebrated its centennial in 2008. Flags bearing the LEO logo were flying in every country where LEO products are available, more than a hundred flags in total. Today, LEO Pharma has an ever growing pipeline with over 4,800 specialists focussing on dermatology and thrombosis.

  • 1912 – The company launched its own Aspirin headache tablet
  • 1917 – The company exported Denmarks first drug, Digisolvin
  • 1940 – The company launched its own Heparin product.
  • 1958-08-13 - Patent filed for Bendrofluazide.
  • 1962 – The company launched Fucidin to be used to treat staphylococcus infections
  • 21st Century & onwards

    In 2015, the company announced it would acquire Astellas Pharmas dermatology business for $725 million.

    References

    Leo Pharma Wikipedia